Navigation Links
Study adds lung damage to harmful effects of arsenic
Date:8/22/2013

A new study confirms that exposure to low to moderate amounts of arsenic in drinking water can impair lung function. Doses of about 120 parts per billion of arsenic in well waterabout 12 times the dose generally considered safeproduced lung damage comparable to decades of smoking tobacco. Smoking, especially by males, made arsenic-related damage even worse.

This is the first population-based study to clearly demonstrate significant impairment of lung function, in some cases extensive lung damage, associated with low to moderate arsenic exposure.

"Restrictive lung defects, such as we saw in those exposed to well-water arsenic, are usually progressive and irreversible," said the study's senior author, Habibul Ahsan, MD, MMedSc, Director of the Center for Cancer Epidemiology and Prevention at the University of Chicago Medicine. "They can lead over time to serious lung disease."

The study, conducted in Bangladesh and published early online in the American Journal of Respiratory and Critical Care Medicine, adds to a growing list of arsenic-related health problems that includes skin, bladder and lung cancers, cardiovascular disease, cognitive deficits and premature death. An estimated 77 million peoplenearly half of the residents of Bangladesh, the world's eighth most populous countrylive in areas where groundwater wells contain harmful amounts of arsenic.

Less is known about exposure to elevated arsenic levels from well water or foods in other parts of the world, including regions in Mexico and the United States. Researchers have recently begun to re-examine foods, such as rice syrup and apple juice, that contain more arsenic than the 10 parts per billion that is allowed in U.S. drinking water.

"It is challenging to conduct rigorous biomedical research in a place like Bangladesh that lacks the infrastructure for such projects," Ahsan said, "but over the last 12 to15 years we have learned how to meet those challen
'/>"/>

Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. UCI-led study reveals how SARS virus hijacks host cells
2. Human brains are hardwired for empathy, friendship, study shows
3. 23andMe conducts the first genetic study of non-syndromic striae distensae (stretch marks)
4. Major study links aging gene to blood cancer
5. BIDMC cardiovascular institute researchers will lead $4 million NIH grant to study micrornas
6. ITN type 1 diabetes study identifies subset of patients with strong response to therapy
7. Rutgers study: Worms may shed light on human ability to handle chronic stress
8. Researchers study seleniums effects on horses
9. Latino families in study eat more fruits and veggies, drink less soda
10. Study finds novel worm community affecting methane release in ocean
11. New study redefines how plaques grow in heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... (UW) have reported for the first time that mammals can ... retinas. Located in the back of the eye, the retina,s ... to the brain. The findings on retina self-repair in ... of the Proceedings of the National Academy of Sciences ...
... Institute of Technology has invited a longtime University of ... and presenting seminars on its campus. Fazle Hussain, ... Engineering, was the sole recipient of the Gordon and ... for Caltech,s division of engineering and applied sciences. The ...
... University have answered a fundamental question of how important ... function, a finding that could provide a new target ... diseases. In a study published this month in ... show for the first time that the specific movements ...
Cached Biology News:Mammals can be stimulated to regrow damaged inner retina nerve cells 2Mammals can be stimulated to regrow damaged inner retina nerve cells 3Celebrated UH researcher invited to Caltech as distinguished scholar 2Scientists present 'moving' theory behind bacterial decision-making 2
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, ... Signaling molecules, became available for purchase in Australia and New ... that RENU 28 works is, if you think about the ... rate of cellular renewal within your body. If you think ... rate of cellular renewal. What RENU 28 does is it ...
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... DRRX ) announced today that a New ... submitted to the U.S. Food,and Drug Administration (FDA). ... formulation of oxycodone intended to treat moderate to ... designed to resist,common methods of prescription drug misuse ...
... to advance Merrimack,s robust pipeline of biologics ... targeting autoimmune disease and cancer, CAMBRIDGE, Mass., ... the discovery and development of,novel treatments for autoimmune disease and ... Series F private equity financing., Existing and new investors ...
... Bioheart, Inc.,(Nasdaq: BHRT ) today announced that ... common stock to the Nasdaq Capital Market. The Company,s,common ... to The,Nasdaq Capital Market at the opening of business ... a tier of the Nasdaq Stock Market for,companies with ...
Cached Biology Technology:New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Bioheart, Inc. to Transfer to Nasdaq Capital Market 2
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
Biology Products: